Previous 10 | Next 10 |
Ovid Therapeutics (OVID) -51% after it misses goal in Angelman syndrome treatment.FuelCell Energy (FCEL) -25% after discloses below-consensus FQ4 revenues; to launch offering.Workhorse Group (WKHS) -22% after Trucks.com reports of further delays in the ...
Atossa Therapeutics (ATOS): Q3 GAAP EPS of -$0.34 in-line.Cash and cash equivalents of ~$9.2MPress Release For further details see: Atossa Therapeutics EPS in-line
SEATTLE, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announced...
Thinly traded nano cap Atossa Therapeutics ([[ATOS]] -5.8%) announces preliminary results from a Phase 1 clinical trial evaluating a nasal spray formulation of AT-301, in development for the potential at-home treatment of COVID-19, in 32 healthy adult volunteers.The candidate was safe and wel...
Atossa Therapeutics ([[ATOS]] +3.1%) has announced blinded preliminary results from Phase 1 study evaluating AT-301 administered by nasal spray, for the treatment of COVID-19.AT-301 under development for at home use, was found to be safe and well tolerated at two different dose...
SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announced...
New Research Points to the People's Liberation Army Hospital in Wuhan, China as the Origin for the Worldwide Coronavirus Pandemic PR Newswire SEATTLE, Oct. 28, 2020 SEATTLE , Oct. 28, 2020 /PRNewswire/ -- A paper published on Zenodo (DOI 10.5281/zenodo.41...
Atossa Therapeutics ([[ATOS]] -2.4%) has completed the enrollment of 32 healthy adult volunteers in an Australia-based Phase 1 study evaluating the safety and tolerability of a nasal spray formulation of AT-301, in development for the potential treatment of non-hospitalized people with COVID-...
SEATTLE, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announced...
SEATTLE, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announces that ...
News, Short Squeeze, Breakout and More Instantly...
Atossa Therapeutics Inc. Company Name:
ATOS Stock Symbol:
NASDAQ Market:
Atossa Therapeutics Inc. Website:
SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the 12-patient 80mg pharmacokinetic (PK) run-in cohort of the Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study has fully...